Microlearning and Broadcast series with ACCOMPANYING med ed threads

Allies in the Race Against Time: Navigating AD with Early Detection, Therapeutic Innovations, and Patient-Centric Care

Overview
Learning Objectives
Faculty and Disclosures

Program Overview

Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder that affects a significant portion of the elderly population and is increasing globally. Recent advancements in disease-modifying therapies have brought hope for slowing or preventing disease progression and improving patient outcomes. However, timely diagnosis and early intervention are crucial for maximizing the likelihood of successful treatment. Clinicians, families, and researchers need to be aware of the importance of early recognition and diagnosis of AD, as well as the latest evidence on biomarkers that aid in early diagnosis. Additionally, understanding the mechanisms of action, efficacy, and safety data for new and emerging disease-modifying therapies is essential.

Target Audience

The educational design of this activity addresses the needs of healthcare professionals who provide care for patients primary care clinicians including internists, family physicians, radiologists, neurologists, nurse practitioners and physician assistants.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Recognize the significance of early recognition and diagnosis of Alzheimer's Disease (AD) in improving patient outcomes and quality of life
  • Explain how to apply knowledge of validated and emerging biomarkers in the early diagnosis of AD to enhance patient-specific treatment decisions
  • Evaluate the mechanisms of action, efficacy, and safety data for disease-modifying therapies newly approved and currently in development for AD, to make informed decisions regarding patient treatment options
  • Review new disease-modifying therapies into patient care plans, promoting adherence to treatment protocols and improving long-term outcomes
  • Discuss how to implement tactics to support patients and families in management strategies and tools to maintain optimal quality of life throughout the AD disease journey

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Chuck Vega, MD
Clinical Professor of Family Medicine
University of California Irvine
Irvine, CA
Disclosures:
Consulting Fee (e.g., Advisory Board): Boehringer Ingelheim
James Galvin,
MD, MPH
Professor of Neurology
Chief, Division of Cognitive Neurology
Director, Comprehensive Center for Brain Health Director, Lewy Body Dementia Research Center of Excellence
Disclosures:
Consulting Fee (e.g., Advisory Board): Biogen, Cognivue, Eisai, Eli Lilly, GE Healthcare, Genentech, Roche
Stock Option Holder: Cognivue
Ian Kremer
Executive Director,
LEAD Coalition
Washington, DC
Nothing to disclose
Carol O'Dell
Speaker and Caregiver Wellness Blogger
Fernandina Beach, FL
Nothing to disclose
This educational activity was supported by an independent educational grant from Eisai, Inc.

Learning program contents